Quick Answer
Immunome Inc. reported Stockholders Equity of $634.34 million for the year ending 2025.
- Immunome Inc. showed an increase of +250.1% in Stockholders Equity from 2024 to 2025.
- This data is from Immunome Inc.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2019: -$29.98 million | Q3 2019: -$32.72 million | Q1 2020: -$38.16 million | Q2 2020: -$40.83 million | Q3 2020: -$49.09 million | Q1 2021: $37.88 million | Q2 2021: $60.62 million | Q3 2021: $54.79 million | Q1 2022: $37.87 million | Q2 2022: $30.28 million | Q3 2022: $23.08 million | Q1 2023: $13.86 million | Q2 2023: $9.34 million | Q3 2023: $6.08 million | Q1 2024: $285.57 million | Q2 2024: $253.84 million | Q3 2024: $214.91 million | Q1 2025: $307.13 million | Q2 2025: $269.27 million | Q3 2025: $263.92 million.
- Over the full 8 years of available data (2018 to 2025), Immunome Inc.'s Stockholders Equity has grown by 2,616.7%.
- Historical annual values: Fiscal year 2025: $634.34 million | Fiscal year 2024: $181.17 million | Fiscal year 2023: $119.88 million | Fiscal year 2022: $16.65 million | Fiscal year 2021: $48.19 million | Fiscal year 2020: $41.35 million | Fiscal year 2019: -$35.63 million | Fiscal year 2018: -$25.21 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: